Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Everett E. Vokes

Concepts (653)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Head and Neck Neoplasms
106
2022
1012
17.230
Why?
Lung Neoplasms
146
2022
2142
15.070
Why?
Carcinoma, Non-Small-Cell Lung
103
2022
994
15.030
Why?
Antineoplastic Combined Chemotherapy Protocols
126
2022
2347
15.020
Why?
Carcinoma, Squamous Cell
75
2021
1037
9.790
Why?
Chemoradiotherapy
32
2022
295
5.870
Why?
Antineoplastic Agents
75
2022
2375
5.810
Why?
Neoplasm Recurrence, Local
50
2022
1197
4.960
Why?
Papillomavirus Infections
12
2022
223
4.240
Why?
Small Cell Lung Carcinoma
20
2021
86
3.960
Why?
Carboplatin
40
2022
273
3.730
Why?
Combined Modality Therapy
63
2021
1688
3.480
Why?
Oropharyngeal Neoplasms
8
2022
120
3.410
Why?
Quinazolines
22
2015
220
3.340
Why?
Protein Kinase Inhibitors
21
2020
572
3.330
Why?
Paclitaxel
40
2022
464
3.160
Why?
Aged
187
2021
18700
3.110
Why?
Neoplasm Staging
74
2022
1940
2.900
Why?
Disease-Free Survival
57
2020
1206
2.790
Why?
Middle Aged
189
2022
25832
2.720
Why?
Humans
326
2022
84808
2.720
Why?
Aged, 80 and over
100
2021
6636
2.450
Why?
Male
206
2022
42330
2.390
Why?
Survival Rate
54
2021
1925
2.360
Why?
Female
208
2022
45277
2.290
Why?
Adult
153
2022
26295
2.220
Why?
Clinical Trials as Topic
24
2021
1212
2.190
Why?
Papillomaviridae
9
2022
145
2.180
Why?
Treatment Outcome
88
2022
7997
2.090
Why?
Cisplatin
31
2022
584
2.080
Why?
Adenocarcinoma
24
2016
1197
2.020
Why?
Induction Chemotherapy
12
2022
142
2.000
Why?
Carcinoma, Small Cell
11
2017
140
1.910
Why?
Taxoids
17
2017
131
1.890
Why?
Survival Analysis
45
2020
1597
1.890
Why?
Indoles
15
2017
335
1.840
Why?
Camptothecin
14
2013
196
1.790
Why?
Radiotherapy Dosage
30
2021
484
1.690
Why?
Antibodies, Monoclonal
20
2021
1531
1.660
Why?
Radiotherapy
15
2011
342
1.630
Why?
Pyrroles
7
2017
221
1.600
Why?
Fluorouracil
25
2014
566
1.580
Why?
Radiation-Sensitizing Agents
6
2013
102
1.560
Why?
Mesothelioma
13
2017
296
1.470
Why?
Hydroxyurea
20
2014
230
1.430
Why?
Laryngeal Neoplasms
5
2013
87
1.390
Why?
Chemotherapy, Adjuvant
20
2015
470
1.390
Why?
Drug Resistance, Neoplasm
13
2021
580
1.380
Why?
Deoxycytidine
14
2012
242
1.360
Why?
Mouth Neoplasms
9
2018
181
1.350
Why?
Angiogenesis Inhibitors
9
2016
293
1.320
Why?
Benzimidazoles
4
2021
137
1.300
Why?
Prognosis
47
2022
3735
1.300
Why?
Proto-Oncogene Proteins c-met
16
2021
202
1.290
Why?
Etoposide
15
2021
199
1.290
Why?
Sirolimus
3
2020
173
1.250
Why?
Medical Oncology
7
2021
335
1.180
Why?
Salvage Therapy
9
2014
224
1.070
Why?
Neoplasms
17
2022
2744
1.040
Why?
Guanine
8
2014
208
1.030
Why?
Maximum Tolerated Dose
13
2018
271
1.000
Why?
Esophageal Neoplasms
5
2012
348
0.990
Why?
Quality of Life
16
2017
1394
0.980
Why?
Clinical Trials, Phase II as Topic
8
2017
171
0.960
Why?
Clinical Trials, Phase III as Topic
10
2021
163
0.950
Why?
Deglutition
9
2020
70
0.950
Why?
Antibodies, Monoclonal, Humanized
18
2018
962
0.950
Why?
Liver Neoplasms
8
2018
652
0.940
Why?
Vascular Endothelial Growth Factor A
10
2013
390
0.940
Why?
Neoplasms, Second Primary
8
2011
251
0.940
Why?
Randomized Controlled Trials as Topic
12
2021
869
0.940
Why?
Pancreatic Neoplasms
4
2010
678
0.920
Why?
Radiotherapy, Conformal
5
2011
87
0.900
Why?
Immunotherapy
6
2021
593
0.900
Why?
Drug Monitoring
2
2022
121
0.880
Why?
Kaplan-Meier Estimate
17
2017
902
0.880
Why?
Disease Progression
22
2021
1487
0.860
Why?
DNA, Viral
1
2022
281
0.860
Why?
Pleural Neoplasms
5
2020
183
0.850
Why?
Neoplasm Metastasis
19
2020
1062
0.850
Why?
Molecular Targeted Therapy
3
2020
277
0.850
Why?
Carcinoma
8
2022
443
0.830
Why?
Cyclooxygenase 2
4
2017
99
0.830
Why?
Carcinoma, Large Cell
7
2014
41
0.810
Why?
Thoracic Neoplasms
4
2018
60
0.770
Why?
Enzyme Inhibitors
7
2014
673
0.770
Why?
Costs and Cost Analysis
1
2019
153
0.740
Why?
Glutamates
6
2014
94
0.720
Why?
Terminal Care
1
2019
139
0.700
Why?
Vinblastine
3
2002
109
0.700
Why?
Drug Administration Schedule
17
2020
973
0.680
Why?
Organoplatinum Compounds
4
2006
99
0.680
Why?
Radiotherapy, Adjuvant
12
2015
310
0.680
Why?
Stomach Neoplasms
3
2011
264
0.650
Why?
Follow-Up Studies
24
2021
3889
0.650
Why?
Time Factors
21
2021
5526
0.640
Why?
Peritoneal Neoplasms
4
2012
181
0.640
Why?
Human papillomavirus 16
2
2015
37
0.640
Why?
Quality of Health Care
2
2019
370
0.640
Why?
Intracellular Signaling Peptides and Proteins
3
2014
384
0.630
Why?
Colorectal Neoplasms
5
2011
887
0.620
Why?
Thionucleotides
2
2008
59
0.620
Why?
Neoadjuvant Therapy
7
2022
281
0.620
Why?
Organ Sparing Treatments
2
2013
37
0.610
Why?
Adenocarcinoma, Bronchiolo-Alveolar
3
2011
20
0.600
Why?
Neoplasms, Squamous Cell
2
2015
19
0.600
Why?
Receptor Protein-Tyrosine Kinases
5
2015
161
0.590
Why?
Speech
2
2013
72
0.580
Why?
Exanthema
3
2014
32
0.570
Why?
Remission Induction
10
2014
716
0.560
Why?
Patient Selection
8
2021
706
0.560
Why?
Platinum Compounds
3
2022
31
0.540
Why?
Pyridines
5
2019
312
0.530
Why?
Neck Dissection
6
2010
72
0.510
Why?
Blood Proteins
1
2014
160
0.510
Why?
Neutropenia
6
2017
223
0.490
Why?
Neoplasm Invasiveness
6
2016
534
0.480
Why?
DNA Repair
2
2014
350
0.480
Why?
Radiotherapy, Intensity-Modulated
5
2016
173
0.470
Why?
Platinum
7
2022
58
0.470
Why?
Cell Line, Tumor
20
2021
2438
0.470
Why?
Mutation
16
2017
3891
0.470
Why?
Protein-Tyrosine Kinases
6
2017
310
0.470
Why?
Proteomics
1
2014
195
0.470
Why?
Publishing
1
2013
91
0.460
Why?
Healthcare Disparities
1
2016
345
0.460
Why?
Antimetabolites, Antineoplastic
4
2013
251
0.460
Why?
DNA-Binding Proteins
3
2015
1215
0.450
Why?
Sulfonamides
9
2014
332
0.450
Why?
Radiosurgery
3
2021
262
0.440
Why?
Proto-Oncogene Proteins c-cbl
3
2017
36
0.440
Why?
Retrospective Studies
25
2021
7883
0.440
Why?
Receptors, Growth Factor
5
2011
56
0.430
Why?
Nasopharyngeal Neoplasms
3
2016
44
0.420
Why?
Gene Expression Regulation, Neoplastic
11
2017
1213
0.420
Why?
Alphapapillomavirus
2
2021
42
0.420
Why?
Lung
3
2013
1119
0.420
Why?
Proportional Hazards Models
9
2019
879
0.420
Why?
Area Under Curve
6
2018
346
0.420
Why?
Signal Transduction
11
2019
3334
0.410
Why?
Antineoplastic Agents, Phytogenic
5
2012
298
0.410
Why?
Maintenance Chemotherapy
3
2020
77
0.400
Why?
Methotrexate
2
2017
264
0.400
Why?
Receptor, EphB4
3
2015
27
0.400
Why?
Age Factors
7
2018
1928
0.380
Why?
Carmustine
2
2006
72
0.380
Why?
Immunoconjugates
2
2021
114
0.380
Why?
Piperazines
8
2019
273
0.380
Why?
O(6)-Methylguanine-DNA Methyltransferase
2
2006
118
0.370
Why?
Dose-Response Relationship, Drug
14
2018
2105
0.370
Why?
Administration, Oral
9
2020
729
0.370
Why?
Cohort Studies
10
2021
2742
0.370
Why?
Arsenicals
1
2008
42
0.370
Why?
Oxides
1
2008
49
0.370
Why?
Proto-Oncogene Proteins
5
2017
680
0.370
Why?
Fatigue
3
2018
173
0.360
Why?
Salivary Gland Neoplasms
4
2011
61
0.350
Why?
Prostatic Neoplasms
5
2011
1505
0.350
Why?
Smoking
6
2014
571
0.350
Why?
Infusions, Intravenous
8
2018
448
0.350
Why?
Double-Blind Method
5
2017
1915
0.350
Why?
Immunohistochemistry
10
2020
1833
0.350
Why?
Indazoles
4
2013
71
0.340
Why?
International Cooperation
3
2018
135
0.340
Why?
Consolidation Chemotherapy
2
2018
21
0.330
Why?
Suramin
2
2004
27
0.330
Why?
Prospective Studies
12
2022
4139
0.330
Why?
Alkyl and Aryl Transferases
2
2003
15
0.330
Why?
Deglutition Disorders
4
2011
90
0.330
Why?
Lymph Nodes
5
2019
541
0.320
Why?
Phosphorylcholine
1
2006
28
0.320
Why?
Pyrimidines
4
2012
403
0.320
Why?
Niacinamide
5
2013
117
0.310
Why?
DNA
1
2012
1303
0.310
Why?
Young Adult
10
2022
6075
0.310
Why?
Thiazoles
3
2012
131
0.310
Why?
Multivariate Analysis
8
2019
1016
0.310
Why?
Cyclin-Dependent Kinase Inhibitor p16
2
2021
102
0.310
Why?
Risk Factors
12
2018
5482
0.300
Why?
Benzenesulfonates
3
2010
64
0.300
Why?
Gene Rearrangement
2
2017
170
0.300
Why?
Anemia
4
2017
132
0.300
Why?
High-Throughput Nucleotide Sequencing
2
2020
419
0.300
Why?
Tubulin Modulators
2
2021
28
0.300
Why?
Gallbladder Neoplasms
1
2005
28
0.300
Why?
Practice Guidelines as Topic
3
2016
1091
0.300
Why?
Mouth
2
2018
54
0.290
Why?
Research Design
4
2015
576
0.290
Why?
Dacarbazine
1
2006
113
0.290
Why?
Placebos
5
2015
233
0.290
Why?
Proto-Oncogene Proteins c-bcl-2
3
2010
200
0.290
Why?
Neovascularization, Pathologic
2
2008
358
0.290
Why?
Bile Duct Neoplasms
1
2005
70
0.290
Why?
Antineoplastic Agents, Alkylating
1
2005
146
0.280
Why?
Confidence Intervals
5
2018
235
0.280
Why?
Boronic Acids
3
2011
55
0.280
Why?
Oligopeptides
1
2005
186
0.270
Why?
Imidazoles
4
2013
169
0.270
Why?
Radiation Dosage
3
2020
227
0.270
Why?
Pyrazines
3
2011
86
0.270
Why?
Pneumonectomy
3
2018
189
0.270
Why?
Mouthwashes
1
2003
5
0.270
Why?
Cyclosporine
1
2005
254
0.270
Why?
Xenograft Model Antitumor Assays
7
2017
465
0.270
Why?
Sarcoma
1
2006
215
0.270
Why?
Feasibility Studies
4
2022
763
0.270
Why?
Positron-Emission Tomography
2
2018
273
0.270
Why?
Radiography
4
2014
877
0.270
Why?
United States
12
2022
6459
0.270
Why?
Viral Vaccines
1
2003
41
0.260
Why?
Tretinoin
2
2021
126
0.260
Why?
Cancer Care Facilities
1
2003
26
0.260
Why?
Immunoblotting
5
2017
280
0.250
Why?
Travel
1
2003
66
0.250
Why?
Quinolones
1
2003
57
0.250
Why?
Tongue Neoplasms
3
2018
52
0.250
Why?
Gene Expression
5
2017
1344
0.240
Why?
Phosphorylation
7
2017
1163
0.240
Why?
Drug Eruptions
2
2017
38
0.230
Why?
Cranial Irradiation
3
2018
36
0.230
Why?
Attitude to Health
1
2004
232
0.230
Why?
Brain Neoplasms
3
2012
808
0.230
Why?
TOR Serine-Threonine Kinases
3
2020
184
0.230
Why?
Precancerous Conditions
1
2003
206
0.230
Why?
Diffusion of Innovation
1
2022
75
0.230
Why?
Chicago
4
2014
1456
0.230
Why?
Thrombocytopenia
2
2017
172
0.220
Why?
Receptors, Vascular Endothelial Growth Factor
3
2010
62
0.220
Why?
Melanoma
2
2005
519
0.220
Why?
Erythroid Precursor Cells
1
2021
32
0.220
Why?
Focal Adhesions
2
2013
70
0.220
Why?
Research Report
1
2021
44
0.220
Why?
Genomics
3
2016
664
0.210
Why?
Polymorphism, Genetic
4
2011
824
0.210
Why?
Paxillin
2
2013
61
0.210
Why?
RNA, Small Interfering
8
2017
568
0.210
Why?
Pyrrolidinones
1
2020
17
0.210
Why?
Sex Factors
4
2019
1097
0.210
Why?
Topoisomerase I Inhibitors
5
2013
36
0.200
Why?
Aminopyridines
1
2019
30
0.200
Why?
Morpholines
1
2019
80
0.190
Why?
Mucositis
2
2017
22
0.190
Why?
Quinolines
1
2020
98
0.190
Why?
Immunosuppressive Agents
1
2005
1030
0.190
Why?
Survival
3
2003
23
0.190
Why?
Predictive Value of Tests
4
2020
1778
0.190
Why?
Pharynx
1
2018
40
0.190
Why?
Epothilones
2
2009
13
0.180
Why?
Granulocyte Colony-Stimulating Factor
4
2011
167
0.180
Why?
Hepatocyte Growth Factor
3
2014
83
0.180
Why?
Phenylurea Compounds
4
2013
110
0.180
Why?
Erythropoietin
3
2013
93
0.180
Why?
Adolescent
6
2022
9293
0.180
Why?
Radiation Injuries
2
2018
159
0.180
Why?
Vascular Endothelial Growth Factor Receptor-2
3
2009
80
0.180
Why?
Health Resources
1
2019
79
0.180
Why?
Depsipeptides
2
2010
30
0.180
Why?
Gene Dosage
7
2013
216
0.180
Why?
Orthodontic Appliances
1
2018
8
0.180
Why?
Dental Alloys
1
2018
7
0.180
Why?
Radiation Pneumonitis
1
2018
16
0.180
Why?
Hemoptysis
1
2018
25
0.180
Why?
DNA Topoisomerases, Type I
3
2013
28
0.180
Why?
Radiotherapy Planning, Computer-Assisted
3
2018
191
0.170
Why?
Tumor Microenvironment
2
2021
336
0.170
Why?
Skin Neoplasms
2
2005
547
0.170
Why?
Vision Disorders
1
2018
69
0.170
Why?
Mice
11
2021
11276
0.170
Why?
Macrophages
1
2021
576
0.170
Why?
Transforming Growth Factor alpha
2
2009
52
0.170
Why?
Gene Expression Profiling
4
2021
1388
0.170
Why?
Retreatment
3
2012
106
0.170
Why?
Genotype
5
2015
1859
0.170
Why?
Carcinoma, Renal Cell
3
2007
402
0.170
Why?
Odds Ratio
4
2008
686
0.170
Why?
Mice, Nude
4
2012
787
0.170
Why?
Tomography, X-Ray Computed
4
2013
2592
0.170
Why?
Intention to Treat Analysis
1
2017
69
0.160
Why?
Geriatric Assessment
1
2018
161
0.160
Why?
Pyrazoles
3
2011
168
0.160
Why?
Animals
14
2021
27277
0.160
Why?
Life Style
1
2018
193
0.160
Why?
In Situ Hybridization, Fluorescence
4
2012
359
0.160
Why?
Paired Box Transcription Factors
2
2014
53
0.160
Why?
Carcinoma, Adenoid Cystic
2
2007
24
0.160
Why?
Patient Acceptance of Health Care
1
2019
234
0.160
Why?
Statistics, Nonparametric
3
2009
326
0.160
Why?
Probability
3
2008
362
0.150
Why?
Lymphatic Metastasis
4
2014
509
0.150
Why?
Kidney Neoplasms
3
2007
595
0.150
Why?
SEER Program
1
2016
193
0.150
Why?
Recombinant Proteins
5
2010
1067
0.150
Why?
Cell Movement
6
2017
756
0.150
Why?
Fractals
1
2015
45
0.150
Why?
Endpoint Determination
1
2015
60
0.150
Why?
Antibody-Dependent Cell Cytotoxicity
1
2015
25
0.150
Why?
Bryostatins
2
2006
15
0.140
Why?
Platelet-Derived Growth Factor
2
2011
68
0.140
Why?
Cell Proliferation
8
2015
1629
0.140
Why?
Injections, Intravenous
2
2006
269
0.140
Why?
Health Status
2
2009
369
0.140
Why?
Radiation, Ionizing
2
2012
126
0.140
Why?
Receptors, Antigen, T-Cell
1
2017
402
0.140
Why?
Incidence
5
2018
1659
0.140
Why?
Isotretinoin
2
2006
22
0.140
Why?
Gene Knockout Techniques
1
2014
75
0.140
Why?
Preoperative Care
3
2009
419
0.140
Why?
Treatment Failure
5
2010
304
0.140
Why?
Mass Screening
2
2013
652
0.140
Why?
Tumor Virus Infections
1
2014
82
0.130
Why?
Cell Survival
5
2017
1017
0.130
Why?
Socioeconomic Factors
1
2016
596
0.130
Why?
Cyclooxygenase 2 Inhibitors
2
2017
34
0.130
Why?
Gene Amplification
2
2018
134
0.130
Why?
Population Groups
1
2013
42
0.130
Why?
Farnesyltranstransferase
2
2003
6
0.130
Why?
Forecasting
2
2021
323
0.130
Why?
Risk Assessment
7
2016
2300
0.130
Why?
Hypopharyngeal Neoplasms
1
2013
15
0.130
Why?
Erythropoiesis
1
2013
50
0.130
Why?
Glucuronosyltransferase
2
2006
188
0.130
Why?
Leukocytes, Mononuclear
2
2005
201
0.130
Why?
Interferon-alpha
3
2010
241
0.130
Why?
Alcohol Drinking
3
2018
276
0.130
Why?
Clinical Protocols
1
2013
158
0.130
Why?
Dehydration
1
2013
23
0.130
Why?
Esophagitis
1
2013
42
0.120
Why?
Pharmacogenetics
2
2008
413
0.120
Why?
Gene Deletion
1
2014
348
0.120
Why?
HeLa Cells
1
2014
512
0.120
Why?
Killer Cells, Natural
1
2015
311
0.120
Why?
Osteoradionecrosis
2
2010
15
0.120
Why?
Universities
2
2010
137
0.120
Why?
Keratin-19
1
2012
11
0.120
Why?
Ketones
1
2012
12
0.120
Why?
Furans
1
2012
18
0.120
Why?
Dexamethasone
2
2004
322
0.120
Why?
Radiation Tolerance
2
2021
175
0.120
Why?
DNA Mutational Analysis
5
2017
538
0.120
Why?
Arachidonate 5-Lipoxygenase
1
2011
23
0.120
Why?
Ribosomal Protein S6 Kinases, 70-kDa
1
2012
48
0.120
Why?
Prostate-Specific Antigen
2
2004
319
0.120
Why?
Phthalazines
1
2011
31
0.110
Why?
Ovarian Neoplasms
2
2008
690
0.110
Why?
Genetic Testing
1
2016
507
0.110
Why?
Evidence-Based Medicine
2
2007
456
0.110
Why?
Cancer Vaccines
1
2013
158
0.110
Why?
RNA, Viral
1
2013
345
0.110
Why?
Image Processing, Computer-Assisted
2
2015
1197
0.110
Why?
Organ Preservation
1
2011
74
0.110
Why?
Radiotherapy, Image-Guided
1
2012
65
0.110
Why?
Genes, ras
1
2011
99
0.110
Why?
Neoplastic Cells, Circulating
1
2011
71
0.110
Why?
Rad51 Recombinase
2
2014
81
0.110
Why?
Periodicals as Topic
1
2013
170
0.110
Why?
Receptor, EphA2
1
2010
6
0.100
Why?
Community Networks
2
2018
35
0.100
Why?
Analysis of Variance
3
2011
965
0.100
Why?
Mucins
1
2010
46
0.100
Why?
Oncogene Proteins, Fusion
1
2011
123
0.100
Why?
Developing Countries
1
2010
75
0.100
Why?
Carcinosarcoma
1
2010
20
0.100
Why?
Antibiotics, Antineoplastic
1
2010
122
0.100
Why?
Antigens, Neoplasm
1
2012
331
0.100
Why?
Health Facilities
1
2009
27
0.100
Why?
Tissue Array Analysis
3
2017
128
0.100
Why?
Postoperative Period
1
2010
313
0.100
Why?
ras Proteins
1
2010
133
0.100
Why?
Biliary Tract Neoplasms
1
2009
32
0.100
Why?
Diarrhea
3
2008
208
0.100
Why?
Disease Models, Animal
4
2021
2342
0.100
Why?
Postoperative Complications
2
2018
2296
0.100
Why?
Hematopoietic Stem Cells
1
2011
289
0.090
Why?
Mesna
1
2008
10
0.090
Why?
Radiotherapy, High-Energy
1
2008
50
0.090
Why?
Receptor, erbB-2
2
2011
193
0.090
Why?
Proto-Oncogene Proteins c-akt
2
2010
320
0.090
Why?
Gene Knockdown Techniques
3
2017
244
0.090
Why?
Macrolides
2
2012
32
0.090
Why?
Radiotherapy, Computer-Assisted
1
2008
25
0.090
Why?
Enteral Nutrition
2
2020
107
0.090
Why?
Patient Care
1
2009
91
0.090
Why?
Eicosanoids
1
2008
16
0.090
Why?
Skin
1
2012
562
0.090
Why?
Lipoxygenase Inhibitors
1
2008
34
0.090
Why?
Mutation, Missense
1
2010
278
0.090
Why?
Fallopian Tube Neoplasms
1
2008
36
0.090
Why?
Lymphoma, Non-Hodgkin
1
2010
265
0.090
Why?
Pain
2
2017
366
0.090
Why?
Pneumonia, Aspiration
1
2007
19
0.090
Why?
Technology, Radiologic
1
2008
102
0.090
Why?
Tumor Suppressor Protein p53
1
2010
372
0.090
Why?
Hypertension
1
2017
1218
0.090
Why?
Azacitidine
1
2008
123
0.080
Why?
Lung Diseases
1
2009
272
0.080
Why?
Tumor Burden
3
2013
289
0.080
Why?
Models, Biological
2
2015
1796
0.080
Why?
Protein Kinase C
1
2008
301
0.080
Why?
Regression Analysis
1
2009
631
0.080
Why?
Epidermal Growth Factor
1
2007
124
0.080
Why?
Tongue
1
2007
60
0.080
Why?
Oncogenes
1
2007
91
0.080
Why?
Multienzyme Complexes
2
2004
66
0.080
Why?
Triazines
1
2007
48
0.080
Why?
Uterine Neoplasms
1
2010
189
0.080
Why?
DNA Primers
3
2014
572
0.080
Why?
Cysteine Endopeptidases
2
2004
91
0.080
Why?
Immunologic Factors
1
2008
165
0.080
Why?
Proteasome Endopeptidase Complex
2
2004
103
0.080
Why?
Tachycardia, Supraventricular
1
2006
21
0.080
Why?
Gastrointestinal Stromal Tumors
1
2006
26
0.080
Why?
Genes, Tumor Suppressor
1
2007
165
0.080
Why?
Neoplasms, Hormone-Dependent
1
2006
39
0.080
Why?
p38 Mitogen-Activated Protein Kinases
1
2006
122
0.080
Why?
Activin Receptors, Type I
1
2005
12
0.080
Why?
Base Sequence
4
2014
2421
0.080
Why?
Observation
2
2020
39
0.080
Why?
Leiomyosarcoma
1
2006
37
0.080
Why?
Phospholipids
1
2006
126
0.080
Why?
Illinois
2
2007
473
0.080
Why?
Surgical Flaps
1
2008
262
0.070
Why?
Receptors, Transforming Growth Factor beta
1
2005
42
0.070
Why?
Anticarcinogenic Agents
1
2006
73
0.070
Why?
Physician's Role
1
2007
187
0.070
Why?
Societies, Medical
2
2007
579
0.070
Why?
Programmed Cell Death 1 Receptor
2
2019
167
0.070
Why?
Carbon Monoxide
1
2005
92
0.070
Why?
Adaptor Proteins, Signal Transducing
1
2007
305
0.070
Why?
Cholangiocarcinoma
1
2005
57
0.070
Why?
Interleukin-2
1
2006
287
0.070
Why?
Otorhinolaryngologic Surgical Procedures
1
2005
15
0.070
Why?
Proto-Oncogene Proteins c-kit
1
2005
82
0.070
Why?
Algorithms
3
2013
1856
0.070
Why?
Hemorrhage
1
2006
251
0.070
Why?
Drug Interactions
1
2005
273
0.070
Why?
Radiometry
1
2004
51
0.070
Why?
Speech Intelligibility
1
2004
10
0.070
Why?
Voice
1
2004
12
0.070
Why?
Dose-Response Relationship, Radiation
2
2018
201
0.070
Why?
Reconstructive Surgical Procedures
1
2008
282
0.070
Why?
Oligonucleotides, Antisense
1
2004
70
0.070
Why?
Leukemia
1
2006
307
0.070
Why?
Case-Control Studies
2
2006
1836
0.070
Why?
Pyrrolidines
1
2004
58
0.070
Why?
Taste
1
2004
27
0.070
Why?
Loss of Heterozygosity
2
2017
87
0.070
Why?
Multicenter Studies as Topic
1
2004
156
0.070
Why?
Administration, Topical
1
2003
98
0.070
Why?
Logistic Models
3
2018
1171
0.070
Why?
Fibroblast Growth Factors
1
2004
85
0.070
Why?
Protease Inhibitors
1
2004
74
0.070
Why?
Nausea
1
2005
170
0.070
Why?
Carcinoma, Transitional Cell
1
2005
157
0.070
Why?
Biopsy, Needle
1
2004
269
0.060
Why?
Thyroid Neoplasms
1
2008
441
0.060
Why?
Vomiting
1
2005
186
0.060
Why?
Mitogen-Activated Protein Kinase 3
1
2003
72
0.060
Why?
Amino Acid Sequence
3
2015
2164
0.060
Why?
Intubation, Gastrointestinal
1
2003
31
0.060
Why?
DNA Methylation
1
2008
583
0.060
Why?
Lactones
1
2003
33
0.060
Why?
Mastication
1
2004
70
0.060
Why?
Bone Neoplasms
1
2006
328
0.060
Why?
Premedication
1
2003
58
0.060
Why?
Cell Transformation, Neoplastic
1
2005
411
0.060
Why?
In Situ Hybridization
1
2003
324
0.060
Why?
Contrast Media
2
2009
1090
0.060
Why?
Mouth Mucosa
1
2003
73
0.060
Why?
Oligonucleotide Array Sequence Analysis
3
2010
706
0.060
Why?
Hospitals, University
1
2003
207
0.060
Why?
Antineoplastic Agents, Hormonal
1
2004
154
0.060
Why?
Cause of Death
1
2004
282
0.060
Why?
STAT3 Transcription Factor
2
2013
72
0.060
Why?
Adenoviridae
1
2003
348
0.060
Why?
Drug Therapy, Combination
2
2019
994
0.060
Why?
Patient Care Team
1
2005
279
0.060
Why?
Mitogen-Activated Protein Kinases
1
2003
235
0.060
Why?
RNA Interference
2
2017
379
0.060
Why?
Carcinoma, Hepatocellular
1
2005
334
0.060
Why?
Registries
1
2006
686
0.060
Why?
Education, Medical, Continuing
1
2003
105
0.060
Why?
Interleukin-6
1
2003
239
0.060
Why?
Receptors, CCR2
1
2021
35
0.060
Why?
Pilot Projects
2
2019
840
0.060
Why?
Adaptation, Psychological
1
2002
158
0.060
Why?
DNA Damage
2
2014
356
0.050
Why?
Referral and Consultation
1
2003
328
0.050
Why?
Apoptosis
3
2014
1782
0.050
Why?
Glucocorticoids
1
2003
362
0.050
Why?
Protein Structure, Tertiary
2
2015
767
0.050
Why?
Comorbidity
1
2004
947
0.050
Why?
Clinical Trials, Phase I as Topic
2
2011
148
0.050
Why?
T-Lymphocytes
2
2006
1313
0.050
Why?
Adaptive Immunity
1
2021
170
0.050
Why?
Interferon-gamma
1
2021
469
0.050
Why?
Infant
1
2006
3157
0.050
Why?
Tumor Necrosis Factor-alpha
1
2003
697
0.050
Why?
Sulindac
2
2009
11
0.050
Why?
CD4-Positive T-Lymphocytes
1
2021
417
0.040
Why?
Oral Health
1
2018
10
0.040
Why?
Activities of Daily Living
1
2019
193
0.040
Why?
Age of Onset
1
2018
320
0.040
Why?
Models, Molecular
2
2015
1311
0.040
Why?
CD8-Positive T-Lymphocytes
1
2021
519
0.040
Why?
Cooperative Behavior
2
2009
170
0.040
Why?
Social Participation
1
2017
13
0.040
Why?
Anorexia
1
2017
29
0.040
Why?
Sensation Disorders
1
2017
23
0.040
Why?
Metals
1
2018
93
0.040
Why?
African Americans
1
2005
1182
0.040
Why?
Transfection
2
2010
946
0.040
Why?
Nerve Tissue Proteins
1
2021
531
0.040
Why?
Dinoprostone
1
2017
72
0.040
Why?
Proteolysis
1
2017
100
0.040
Why?
Transcriptome
1
2021
534
0.040
Why?
Weight Loss
1
2019
244
0.040
Why?
Dyspnea
1
2017
80
0.040
Why?
ROC Curve
1
2019
768
0.040
Why?
Bronchoscopy
1
2017
151
0.040
Why?
Decision Making
1
2002
626
0.040
Why?
Polymerase Chain Reaction
2
2009
1000
0.040
Why?
Mice, Knockout
1
2021
1993
0.040
Why?
Analgesics, Opioid
1
2020
382
0.040
Why?
Cell Line
2
2011
2625
0.040
Why?
Molecular Sequence Annotation
1
2015
75
0.040
Why?
Receptors, IgG
1
2015
51
0.040
Why?
Thalidomide
1
2015
54
0.040
Why?
Breast Neoplasms
2
2005
2825
0.040
Why?
Human papillomavirus 18
1
2014
15
0.040
Why?
Safety
2
2008
174
0.030
Why?
Protein Interaction Maps
1
2014
50
0.030
Why?
Sequence Alignment
1
2015
365
0.030
Why?
Erythrocyte Count
1
2013
23
0.030
Why?
Biopsy
2
2009
1190
0.030
Why?
Genes, BRCA2
1
2014
149
0.030
Why?
Autopsy
1
2013
110
0.030
Why?
DNA Copy Number Variations
1
2014
181
0.030
Why?
Genes, BRCA1
1
2014
187
0.030
Why?
Gastrostomy
1
2013
76
0.030
Why?
Sequence Analysis, RNA
1
2014
207
0.030
Why?
Immunoglobulin G
1
2015
485
0.030
Why?
Drug Synergism
1
2013
334
0.030
Why?
Herpesvirus 4, Human
1
2013
115
0.030
Why?
Ethers, Cyclic
1
2012
7
0.030
Why?
Macrophage Colony-Stimulating Factor
1
2012
19
0.030
Why?
Germ-Line Mutation
1
2015
301
0.030
Why?
Thrombospondin 1
1
2011
22
0.030
Why?
GPI-Linked Proteins
1
2011
55
0.030
Why?
Alleles
2
2006
1120
0.030
Why?
Enzyme Activation
1
2013
739
0.030
Why?
Caenorhabditis elegans
1
2014
210
0.030
Why?
Immunoenzyme Techniques
1
2012
332
0.030
Why?
Magnetic Resonance Imaging
1
2004
3309
0.030
Why?
Drug Dosage Calculations
1
2011
17
0.030
Why?
Chemoradiotherapy, Adjuvant
1
2011
35
0.030
Why?
California
1
2011
142
0.030
Why?
Lymphopenia
1
2011
31
0.030
Why?
Computational Biology
1
2015
535
0.030
Why?
Real-Time Polymerase Chain Reaction
1
2012
288
0.030
Why?
src-Family Kinases
1
2011
76
0.030
Why?
Thorax
1
2011
54
0.030
Why?
Organs at Risk
1
2011
47
0.030
Why?
Barrett Esophagus
1
2012
132
0.030
Why?
DNA Breaks, Double-Stranded
1
2011
56
0.030
Why?
Gene Regulatory Networks
1
2013
287
0.030
Why?
HEK293 Cells
1
2013
648
0.030
Why?
Cyclin D1
1
2010
82
0.030
Why?
Endonucleases
1
2010
21
0.030
Why?
Lymphoma, Mantle-Cell
1
2010
32
0.030
Why?
Leucovorin
1
2010
220
0.030
Why?
National Cancer Institute (U.S.)
1
2010
67
0.030
Why?
Histone Deacetylases
1
2010
63
0.030
Why?
Extracellular Signal-Regulated MAP Kinases
1
2010
119
0.030
Why?
Hospitals, Veterans
1
2009
19
0.030
Why?
Lymphoma, Follicular
1
2010
69
0.030
Why?
Paraffin Embedding
1
2010
81
0.030
Why?
Clinical Trials Data Monitoring Committees
1
2009
6
0.030
Why?
Chromosomes, Human, Pair 11
1
2010
108
0.030
Why?
Peptides
1
2013
646
0.020
Why?
Semaphorins
1
2009
17
0.020
Why?
Hydroxamic Acids
1
2009
48
0.020
Why?
Molecular Sequence Data
1
2015
3187
0.020
Why?
Proto-Oncogene Proteins p21(ras)
1
2010
145
0.020
Why?
Leukemia, Lymphocytic, Chronic, B-Cell
1
2010
130
0.020
Why?
Lymphoma, Large B-Cell, Diffuse
1
2010
127
0.020
Why?
Wound Healing
1
2012
346
0.020
Why?
Mutagenesis, Site-Directed
1
2010
284
0.020
Why?
Pneumonia
1
2010
158
0.020
Why?
Transplantation, Heterologous
1
2010
369
0.020
Why?
Carcinoma, Neuroendocrine
1
2009
28
0.020
Why?
Hematinics
1
2008
10
0.020
Why?
Phorbol Esters
1
2008
30
0.020
Why?
Demography
1
2009
164
0.020
Why?
Community Health Services
1
2009
72
0.020
Why?
Inhibitory Concentration 50
1
2008
64
0.020
Why?
Bone Marrow
1
2010
424
0.020
Why?
Postoperative Care
1
2009
232
0.020
Why?
Cell Cycle
1
2010
522
0.020
Why?
Genes, erbB-1
1
2008
16
0.020
Why?
Cytochrome P-450 CYP3A
1
2008
42
0.020
Why?
Blotting, Western
1
2010
833
0.020
Why?
Cytochrome P-450 Enzyme System
1
2008
78
0.020
Why?
Flow Cytometry
1
2010
731
0.020
Why?
Drug Delivery Systems
1
2009
219
0.020
Why?
Exons
1
2009
464
0.020
Why?
Topotecan
1
2007
46
0.020
Why?
Mice, Inbred Strains
1
2008
332
0.020
Why?
ATP-Binding Cassette Transporters
1
2008
142
0.020
Why?
Health Transition
1
2007
2
0.020
Why?
Blood Pressure
1
2013
1207
0.020
Why?
Tamoxifen
1
2008
167
0.020
Why?
Fluoroscopy
1
2007
130
0.020
Why?
Tumor Cells, Cultured
1
2008
1089
0.020
Why?
Academic Medical Centers
1
2009
396
0.020
Why?
Gene Expression Regulation, Enzymologic
1
2008
224
0.020
Why?
Cell Nucleus
1
2009
591
0.020
Why?
Aging
1
2011
672
0.020
Why?
Video Recording
1
2007
191
0.020
Why?
Urogenital Neoplasms
1
2005
17
0.020
Why?
Stem Cells
1
2008
358
0.020
Why?
Mandibular Diseases
1
2005
16
0.020
Why?
Body Mass Index
1
2009
790
0.020
Why?
Polyethylene Glycols
1
2008
394
0.020
Why?
Up-Regulation
1
2008
717
0.020
Why?
Pleural Effusion
1
2004
48
0.020
Why?
Sequence Deletion
1
2005
214
0.020
Why?
Central Nervous System Neoplasms
1
2005
81
0.020
Why?
Gastrointestinal Neoplasms
1
2005
107
0.020
Why?
Receptors, Endothelin
1
2004
13
0.020
Why?
Genital Neoplasms, Female
1
2005
90
0.020
Why?
Antidiarrheals
1
2004
14
0.020
Why?
Research
1
2005
264
0.020
Why?
Biomedical Research
1
2008
359
0.020
Why?
Neoplasm Proteins
1
2008
550
0.020
Why?
Benzamides
1
2005
220
0.020
Why?
Bilirubin
1
2004
129
0.020
Why?
Transforming Growth Factor beta
1
2005
285
0.020
Why?
Genome-Wide Association Study
1
2011
1544
0.020
Why?
Gadolinium DTPA
1
2004
264
0.020
Why?
Hematologic Neoplasms
1
2005
300
0.010
Why?
Biological Availability
1
2002
105
0.010
Why?
Risk
1
2004
702
0.010
Why?
Cytokines
1
2006
780
0.010
Why?
Severity of Illness Index
1
2007
1793
0.010
Why?
Child
1
2012
6928
0.010
Why?
Muscle, Skeletal
1
2004
446
0.010
Why?
Diagnosis, Differential
1
2005
1612
0.010
Why?
Colonic Neoplasms
1
2004
565
0.010
Why?
Phenotype
1
2005
2324
0.010
Why?
Liver
1
2004
1262
0.010
Why?
Anti-Bacterial Agents
1
2004
829
0.010
Why?
Genetic Variation
1
2004
1377
0.010
Why?
Genetic Predisposition to Disease
1
2005
2248
0.010
Why?
Vokes's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_